Funktionelle gastrointestinale Störungen

Ärzte sind oft unsicher bei der Diagnose einer funktionellen gastrointestinalen Störung, Patienten lehnen die Diagnose häufig ab. Die Behandlung wird von beiden Seiten häufig frustran erlebt. Dieser Beitrag stellt Grundzüge einer abgestuften biopsychosozialen Diagnostik und Therapie von funktionellen gastrointestinalen Störungen vor. Die Darstellung der therapeutischen Optionen soll Sicherheit geben und zu einer größeren Zufriedenheit in der Arzt-Patienten-Interaktion führen.

Abstract

Approximately 50 % of chronic gastrointestinal symptoms in primary care can be attributed to functional gastrointestinal disorders (FGID). The most frequent gastrointestinal disorders are functional dyspepsia and irritable bowel syndrome. FGID are heterogenous with regards to the amount of symptoms and associated patient’s impairment as well as to the underlying pathophysiological mechanisms. The biopsychosocial model of FGID assumes that biological, psychological and social factors interact in the predisposition to and in the initiation and course of FGID. The Rome Foundation defines FGID as disorders of the brain-gut interaction.

Some physicians are hesitant to diagnose FGID due to the lack of specific biomarkers and/or structural changes in the gastrointestinal tract. In addition, some FGID to not respond well to conventional medications. Some patients are reluctant to accept the diagnosis of a FGID because they are afraid that a serious somatic disease has been missed and/or to be diagnosed as mentally ill.

The use of interdisciplinary evidence-based guidelines for diagnosis and management of FGID can increase the certainty of diagnosis and the therapeutic options for physicians. In addition, these guidelines include recommendations how to explain the disorder and the management to the patient to establish a trustful doctor-patient relationship.

FGID are diagnosed by the history of a typical cluster of symptoms and by guideline – recommended exclusion of somatic gastrointestinal disorders. FGID should be managed according to the main symptoms, the associated impairment and patients’ preferences in a graduated approach by education and by dietary, pharmacological and psychological treatments.

Schlüsselwörter

funktionelle gastrointestinale Störungen - biopsychosoziales Modell - interdisziplinäre Leitlinien - abgestufte Behandlung

Key words

functional gastrointestinal disorders - biopsychosocial model - interdisciplinary guidelines - graduated treatment approach

Publication History

Article published online:
11 May 2022

• Literatur

• 1 Black CJ, Drossman DA, Talley NJ. et al. Functional gastrointestinal disorders: advances in understanding and management. Lancet 2020; 396: 1664-1674
• 2 Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology 2016; 150: 1257-1261
• 3 Layer P, Andresen V, Allescher H. et al Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie des Reizdarmsyndroms. Deutsche Gesellschaft für Verdauungs- und Stoffwechselerkrankungen. 2021 Im Internet (Stand: 29.01.2022): https://www.awmf.org/leitlinien/detail/ll/021-016.html
• 4 Häuser W, Layer P, Henningsen P. et al. Functional bowel disorders in adults. Dtsch Arztebl Int 2012; 109: 83-94
• 5 Roenneberg C, Sattel H, Schaefert R. et al. Funktionelle Körperbeschwerden. Dtsch Arztebl Int 2018; 116: 553-560
• 6 Bundesinstitut für Arzneimittel und Medizinprodukte. ICD-10-GM. Im Internet 29.01.2022: https://www.dimdi.de/dynamic/de/klassifikationen/icd/icd-10-gm
• 7 Bundesinstitut für Arzneimittel und Medizinprodukte. ICD-11. Revision der ICD der WHO. Im Internet (Stand: 29.01.2022): https://www.dimdi.de/dynamic/de/klassifikationen/icd/icd-11
• 8 Hausteiner-Wiehle C. Funktionelle Körperbeschwerden: Klinische Vielfalt, diagnostische Herausforderungen, therapeutische Prinzipien. Dtsch Med Wschr 2022; 147: 587-594
• 9 Petersen MW, Schröder A, Jørgensen T. et al. Prevalence of functional somatic syndromes and bodily distress syndrome in the Danish population: the DanFunD study. Scand J Public Health 2020; 48: 567-576
• 10 Ford AC, Mahadeva S, Carbone MF. et al. Functional dyspepsia. Lancet 2020; 396: 1689-1702
• 11 Ford AC, Sperber AD, Corsetti M. et al. Irritable bowel syndrome. Lancet 2020; 396: 1675-1688
• 12 Häuser W, Marschall U, Layer P. et al. The Prevalence, Comorbidity, Management and Costs of Irritable Bowel Syndrome. Dtsch Arztebl Int 2019; 116: 463-470
• 13 Goodoory VC, Mikocka-Walus A, Yiannakou Y. et al. Impact of Psychological Comorbidity on the Prognosis of Irritable Bowel Syndrome. Am J Gastroenterol 2021; 116: 1485-1494
• 14 Black CJ, Thakur ER, Houghton LA. et al. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut 2020; 69: 1441-1451
• 15 Andresen V, Keller J, Layer P. Funktionelle Dyspeppsie („Reizmagen“). In: Rosien U, Berg T, Layer P. (Hrsg) Facharztwissen Gastroenterologie und Hepatologie. 2. Aufl.. München: Elsevier; 2021: 416-420